Reporter brief
Metformin did not slow FEV1 decline in COPD patients over 3 years: RCT
What happened
This was a prospective, multicentre, double-blind, placebo-controlled randomised trial that tested whether metformin 850 mg twice daily could slow lung function decline in COPD patients with emphysema. Participants took metformin or placebo for 3 years, with the primary outcome being change in FEV1 (a measure of lung function). The abstract provided describes only the study protocol without reporting the actual results or effect sizes.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1
- Design
- Rct
- Sample
- —
- Journal
- Fundación Instituto de Investigación Sanitaria de Navarra
- Published
- May 31, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.